Share Icon Health Study Area: Cardiovascular Disease Chevron Icon Health Study Area: Genitourinary For Patients Health Study Area: Lung Cancer Page Icon Phone Icon For Caregivers Health Study Area: AutoImmune Disease Health Study Area: Melanoma Location Icon Print YouTube Icon For Parents Health Study Area: Lung Cancer Print Created with Sketch. Help Icon Green Check Icon Search Icon Instagram Created with sketchtool. Direction Arrow Icon Error Icon For Parents Health Study Area: Blood Cancer Help Icon Health Study Area: NASH Gender Both Bookmark Icon Health Study Area: Melanoma Created with Sketch. Glossary Print Health Study Area: Blood Cancer Health Study Area: Genitourinary Health Study Area: Gastrointestinal Cancer Mobile Menu Icon Created with Sketch. Health Study Area: Cardiovascular Disease Health Study Area: Women's Cancer Communities Map Icon Created with Sketch. For Caregivers Health Study Area: Fibrosis Health Study Area: AutoImmune Disease FAQs Health Study Area: Head and Neck Cancer Created with Sketch. For Clinicians Chevron Right Icon Gender Female Health Study Area: Breast Cancer Direction Arrow Icon Gender Both Right Arrow Icon LinkedIn Icon Green Check Icon Gender Male Health Study Area: Fibrosis For Patients Twitter Icon Email Icon Facebook Icon Health Study Area: Gastrointestinal Cancer Health Study Area: Head and Neck Cancer For Clinicians External Link Icon

Menü

Klinische Studien von BMS suchen
BMS-Symbol für "Aktive Studie, für die noch nicht rekrutiert wird"

Active, Not Recruiting

Studien-Nr. CA061-1011  |   NCT07015983

A Study of CC-97540 (BMS-986353), CD19-Targeted NEX-T CAR T Cells, in Participants With Active SLE Despite Immunosuppressants (Breakfree-SLE)

Warnsymbol
In diese Studie werden leider keine neuen Patient:innen aufgenommen, sie ist aber weiterhin aktiv.
Sie können auf die Schaltfläche "Prüfen Sie, ob eine Studie für Sie infrage kommt“ und einige Fragen zu Ihrer Gesundheit beantworten, um herauszufinden, ob eine andere Studie für Sie infrage kommt.
Kommt die Studie für Sie infrage

Zusammenfassung

  • Phase 2
  • Symbol für männliches und weibliches Geschlecht
  • 16+
    Altersgruppe
  • BMS-Symbol für "Aktive Studie, für die noch nicht rekrutiert wird"
    Active, Not Recruiting

Überblick

The purpose of this study is to evaluate the efficacy, safety and drug levels of CC-97540 in participants with active systemic lupus erythematosus (SLE) including lupus nephritis with inadequate response to glucocorticoids and at least 2 immunosuppressants.

Druckmedium-alt Druckmedium
email E-Mail

Wichtigste Einschlusskriterien

Key

Einschlusskriterien

Symbol für Einschlusskriterien img
  • Participants must meet EULAR/ACR 2019 criteria for SLE.
    1. Participants must have an inadequate response to appropriate doses of glucocorticoids and ≥ 2 immunosuppressant therapies, used for at least 3 months.
      1. Participants must have active disease when signing ICF. Key

        Ausschlusskriterien

        Symbol für Ausschlusskriterien
        :
        • Participants must not have other diseases, conditions, or treatments that may confound interpretation of the effects of CC-97540 in SLE.
          1. Uncontrolled or clinically significant cardiovascular conditions or CNS pathology participants must not have prior history of malignancies or lymphoproliferative disease, unless the participant has been free of the disease for ≥ 2 years, except for some non-invasive malignancies.
            1. IOCBP who are pregnant, nursing, or breastfeeding, or who intend to become pregnant during participation in the study.
              1. Participants must not have prior treatment with CAR T cell therapy, genetically modified T cell therapy, or stem cell transplant. Washout periods may be required.
                1. Participants must not have received live vaccines within 6 weeks before CC-97540 administration.
                  1. Participant must not have inadequate organ function.
                    1. Other protocol defined inclusion/exclusion criteria apply.
                      Zusätzliche Informationen*

                      Behandlungsmöglichkeiten

                      Studienarme

                      ZUGEWIESENE BEHANDLUNG

                      Studienarme

                      Experimental: Administration of CC-97540

                      ZUGEWIESENE BEHANDLUNG
                      • Drug: CC-97540, Fludarabine, Cyclophosphamide

                      Unterstützen Sie uns dabei, Ihre Nutzung der Website zu optimieren! Teilen Sie Ihr Feedback mit unserem Team bei BMS Clinical Trials, um die Nutzung der Webseite, Ihre Erfahrungen und die anderer zu verbessern. Vielen Dank!